Atorvastatin Calcium Tablet, Film Coated
Product Images NDC 82804-054

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Atorvastatin Calcium (NDC 82804-054). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Chemical Structure (Chemical Structure)

Chemical Structure (Chemical Structure)
FDA Label Image

82804-054-30 (Container Label 20mg)

82804-054-30 (Container Label 20mg)
Based on the provided text, the description of the product is as follows: This is a package of Atorvastatin Calcium tablets, each containing 20mg of the active ingredient. The package contains 30 tablets. The tablets are oval-shaped, white in color, and have "A5" debossed on one side. The tablets are film-coated. The package is manufactured by Proficient Rx LP and distributed by the same. The lot number of the package is 00000. The package is intended for prescription use only. The tablets are to be stored at a temperature range of 20°C to 25°C (68°F to 77°F) and should be kept out of the reach of children. The expiration date of the package is not readable in the provided text.*
FDA Label Image

Figure 1.jpg (Figure1)

Figure 1.jpg (Figure1)
FDA Label Image

Figure 2.jpg (Figure2)

Figure 2.jpg (Figure2)
Cumulative Hazard (%): - The cumulative hazard is displayed as a percentage. - The values for cumulative hazard are 15% and 10%. HR 0.63 (0.48-0.83) p=0.001: - HR (Hazard Ratio) is 0.63. - The 95% confidence interval for the HR is between 0.48 and 0.83. - The p-value associated with the HR is 0.001, suggesting a statistically significant result. Time to First Primary Endpoint Through Four (4) Years of Follow-up (Years): - This information represents the time it took for the first primary endpoint to occur, measured in years. - The follow-up period for this analysis is four (4) years.*
FDA Label Image

Figure 3.jpg (Figure3)

Figure 3.jpg (Figure3)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.